Communicating the benefits and harms of treatments

被引:27
|
作者
Akobeng, A. K. [1 ]
机构
[1] Booth Hall Childrens Hosp, Cent Manchester & Manchester Childrens Univ Hosp, Dept Paediat Gastroenterol, Manchester M9 7AA, Lancs, England
关键词
D O I
10.1136/adc.2008.137083
中图分类号
R72 [儿科学];
学科分类号
100202 ;
摘要
Although various measures can be used to describe the benefits and harms of treatments, not all of these clearly show the benefits or otherwise of treatments in a clinically useful way. Relative risk and relative risk reduction are commonly used to describe the results of studies, but they are of limited clinical usefulness as they do not take baseline risks into account and tend to exaggerate the results of studies. Absolute risk measures such as the number needed to treat (NNT) and the number needed to harm (NNH) allow risk to be expressed in a much more clinically relevant way. The absolute risk measures reflect baseline risk and more accurately indicate the magnitude of the treatment effect. However, because they vary according to the baseline risk of the population, they are of limited generalisability, and the published NNT of a treatment in one population cannot be directly applied to another population with a different baseline risk. There are, however, a number of simple methods which can allow us to estimate NNTs or NNHs for our own patients based on published data. The benefits of a treatment (expressed as the NNT) and the harms of the treatment (expressed as the NNH) can be combined into a single ratio called the likelihood of being helped or harmed (LHH). LHH can be adjusted for individual patients by taking account of their own values and unique circumstances.
引用
收藏
页码:710 / 713
页数:4
相关论文
共 50 条
  • [1] Communicating Benefits and Harms of Treatment
    Nardone, David A.
    [J]. ANNALS OF INTERNAL MEDICINE, 2011, 155 (11) : 793 - 793
  • [2] Communicating the Benefits and Harms of Cancer Screening
    Lindsay J. L. Forbes
    Amanda J. Ramirez
    [J]. Current Oncology Reports, 2014, 16
  • [3] Communicating the Benefits and Harms of Cancer Screening
    Forbes, Lindsay J. L.
    Ramirez, Amanda J.
    [J]. CURRENT ONCOLOGY REPORTS, 2014, 16 (05)
  • [4] Communicating the benefits and harms of anticancer drugs
    Feeney, Timothy
    Villanueva, Tiago
    Price, Amy
    [J]. BMJ-BRITISH MEDICAL JOURNAL, 2023, 380
  • [5] Communicating the uncertainty of harms and benefits of medical interventions
    Politi, Mary C.
    Han, Paul K. J.
    Col, Nananda F.
    [J]. MEDICAL DECISION MAKING, 2007, 27 (05) : 681 - 695
  • [6] Communicating to citizens the benefits, harms and risks of preventive interventions
    Thornton, Hazel
    [J]. JOURNAL OF EPIDEMIOLOGY AND COMMUNITY HEALTH, 2010, 64 (02) : 101 - 102
  • [7] Patients' Value of Benefits and Harms of Migraine Treatments
    Coplan, Paul M.
    Hauber, Brett A.
    Mohamed, Ateesha
    Johnson, Reed F.
    Levitan, Bennett
    [J]. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2010, 19 : S45 - S45
  • [8] Understanding and communicating risk Measures of outcome and the magnitude of benefits and harms
    Bell, Neil R.
    Dickinson, James A.
    Grad, Roland
    Singh, Harminder
    Kasperavicius, Danielle
    Thombs, Brett D.
    [J]. CANADIAN FAMILY PHYSICIAN, 2018, 64 (03) : 181 - 185
  • [9] Communicating Data About the Benefits and Harms of Treatment A Randomized Trial
    Woloshin, Steven
    Schwartz, Lisa M.
    [J]. ANNALS OF INTERNAL MEDICINE, 2011, 155 (02) : 87 - U70
  • [10] Balancing benefits and harms of treatments for acute bipolar depression
    Ketter, Terence A.
    Miller, Shefali
    Dell'Osso, Bernardo
    Calabrese, Joseph R.
    Frye, Mark A.
    Citrome, Leslie
    [J]. JOURNAL OF AFFECTIVE DISORDERS, 2014, 169 : S24 - S33